A new round of Congressional legislation targets China. Will they pass? And when they do, will the government take action, or issue endless reviews and investigations as China marches on, and America risks stalling out post-pandemic.
CPA sent the following to U.S. Senators Rob Portman (R-OH), Tom Carper (D-DE), and 38 other members of the Senate regarding their recent letter to
President Biden said that his climate change policies will create millions of jobs if he favors American manufacturing. If not, any sort of green new deal just ends up being a China job’s program. Here’s China’s position in global wind and solar manufacturing today.
Yellen takes a pass on calling Vietnam, others, currency manipulators. That puts the onus on Commerce and the USTR to do something about it. Will they?
Worried about climate change, Senator Wyden and the Democrats want to give cleantech and energy companies permanent tax breaks. He faces some serious opposition.
McKinsey has turned the corner on the Asia-centric model of globalization. It’s a “now-or-never” moment for US manufacturing. Here’s where CPA sees eye-to-eye.
From retail investors in China ETFs, to Wall Street’s largest investment firms, China’s new technologies can always count on tens of millions of dollars of inflows from Americans. What do we get in return?
How do we bring back generic drug manufacturing to the United States in order to be less reliant on India, China? A National Academies of Science conference brings in some experts to try and answer that, including the chair of CPA Healthcare Committee.
The trend continues. A Chinese couple indicted over biotech trade secret’s lifted from Ohio research hospital.
A recent Senate Finance Committee hearing on the China threat bodes well for ongoing bipartisan support for American manufacturing. There are right ways and wrong ways to go about this. The wrong way: waiting for allies. The right way: revamping tariff laws that makes reindustrialization profitable.
